- Market Capitalization, $K 1,054,210
- Shares Outstanding, K 114,588
- Annual Sales, $ 46,550 K
- Annual Income, $ -75,240 K
- 60-Month Beta 1.23
- Price/Sales 22.84
- Price/Cash Flow N/A
- Price/Book 10.88
|Period||Period Low||Period High||Performance|
| || |
+0.19 (+1.99%)since 06/28/21
| || |
-0.85 (-8.28%)since 04/28/21
| || |
+0.87 (+10.05%)since 07/28/20
/PRNewswire/ -- (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report second quarter 2021 financial results on , after the U.S. financial markets...
and , /PRNewswire/ -- (Dynavax, Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines and (BE), a -based vaccine and pharmaceutical company, today announced...
/PRNewswire/ -- The report has been added to offering.
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 51,000 shares of Dynavax common stock as inducements...
/PRNewswire/ -- While the economy is slowly coming back to normal, concerns over the hyper-transmissible delta variant are rising. According to the CDC, the number of new cases in rose 10% this week....
Slow Trading Can't Stop S&P, NASDAQ From Setting New Records
/PRNewswire/ -- (Nasdaq: DVAX) today announced that, in connection with the appointment of John Slebir as Senior Vice President, General Counsel on , the Company granted him a non-statutory stock option...
/PRNewswire/ -- (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that , Chief Executive Officer, will present virtually at the Goldman...
Reportlinker.com announces the release of the report "Oligonucleotide Therapy Global Market Report 2021: COVID 19 Growth And Change to 2030" - https://www.reportlinker.com/p06090627/?utm_source=GNW
|S&P Biotech SPDR|
|Bioshares Biotech Clinical Trial|
|Etfmg Treatments Testing and Advancements ETF|
|Micro-Cap Ishares ETF|
|USA Min Vol Small-Cap Ishares Edge MSCI ETF|